[HTML] springer.comFull View

[HTML][HTML] Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - Cardiovascular …, 2022 - Springer
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …
被引用次数：27 相关文章

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - CARDIOVASCULAR …, 2022 - publicatt.unicatt.it
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice… - Cardiovascular …, 2022 - search.proquest.com
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario, M Lorusso… - 2022 - pubmed.ncbi.nlm.nih.gov
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice… - Cardiovascular …, 2022 - research.uniupo.it
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - CARDIOVASCULAR …, 2022 - iris.uniupo.it
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - Cardiovascular …, 2022 - europepmc.org
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …
[HTML] biomedcentral.com

[HTML][HTML] Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice… - Cardiovascular …, 2022 - cardiab.biomedcentral.com
Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D),
treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality …

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.

L Leccisotti, F Cinti, GP Sorice… - Cardiovascular …, 2022 - search.ebscohost.com
Objective: Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …
[HTML] nih.gov

[HTML][HTML] Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

L Leccisotti, F Cinti, GP Sorice, D D'Amario… - Cardiovascular …, 2022 - ncbi.nlm.nih.gov
Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2
diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces …